High altitude renal syndrome: four elements or one source?
Open Access
- 3 April 2025
- journal article
- review article
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2482125
Abstract
High Altitude Renal Syndrome (HARS) is a clinical syndrome characterized by polycythemia, hyperuricemia, hypertension, and albuminuria at high altitudes. This review emphasizes hypoxia-induced High Altitude Polycythemia (HAPC) as its core driver. In 2014, the 6th Qinghai International Conference on Mountain Medicine and High Altitude Physiology established international diagnostic criteria for HAPC (hemoglobin ≥210g/L in males, ≥190g/L in females). HAPC triggers systemic hypoxia, leading to hyperuricemia via uric acid overproduction and reduced renal excretion, hypertension from hemodynamic changes, and glomerular injury through erythrocytosis. Pathological mechanisms involve HIF-2α-mediated glomerular hypertrophy and podocyte damage. Treatment strategies target HAPC and downstream effects. Carbonic anhydrase inhibitors (e.g., acetazolamide) reduce hematocrit and improve oxygen saturation, but newer agents like methazolamide and dichlorphenamide offer equivalent efficacy with fewer side effects (e.g., reduced central nervous system toxicity). For severe cases, descending to lower altitudes remains the gold standard. Additional interventions include calcium channel blockers (nifedipine), urate-lowering drugs, and experimental therapies such as HIF-2α inhibitors (PT2385) and endothelin receptor antagonists (matitan). This analysis underscores HAPC as the primary etiology of HARS, advocating revised diagnostic criteria and treatment prioritization.Keywords
Funding Information
- 2022 Anhui Province Clinical Medical Research Transformation Special Project (202204295107020042)
- Tibet Autonomous Region Natural Science Foundation Group-style Medical Aid Project for Tibet (XZZR202402021)
This publication has 53 references indexed in Scilit:
- Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitudeJournal Of Hypertension, 2011
- Blood Pressure Responses in Young Adults First Exposed to High Altitude for 12 Months at 3550 mHigh Altitude Medicine & Biology, 2009
- Chronic Kidney Disease at High AltitudeJournal of the American Society of Nephrology, 2008
- AcetazolamideAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemiaAmerican Journal of Kidney Diseases, 2002
- Hypertension and renal disease: role of microalbuminuria.1996
- High altitude-induced albuminuria in normal man is enhanced by infusion of low-dose dopamineScandinavian Journal of Clinical and Laboratory Investigation, 1996
- Effect of Acute Polycythemia on Newborn Renal Hemodynamics and FunctionPediatric Research, 1982
- High Altitude HyperuricemiaExperimental Biology and Medicine, 1968
- Renal Function in Man Acclimatized to High AltitudeJournal of Applied Physiology, 1957